MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Of note, in chronic myeloid leukemia (CML), it was reported that lncRNA HULC dysregulates the miR-150-5p/MCL-1 axis to impact imatinib resistance [91].